Medicines for All Institute’s Post

"It started with a Bill & Melinda Gates Foundation-funded project at Virginia Commonwealth University’s (VCU) College of Engineering, focused on using advanced technologies to develop a more cost-effective way to manufacture the HIV/AIDS therapy, nevirapine. In 2017, additional funding from the Gates Foundation allowed for the university to officially establish the Medicines for All Institute (M4ALL) and apply its optimized active pharmaceutical ingredient (API) development platform to a broader array of lifesaving vaccines and treatments." Medicines for All Institute is proud to be a part of the changing landscape of the State of Virginia and all of the work being done to improve access to medicines globally.

M4ALL is proud to contribute to the USAID-funded PQM+ program and to partner with US Pharmacopeia and Chemical Process Technologies on this important project to make #TB treatment more accessible. We have had the privilege of working on low-cost processes for several high-priority TB drugs and will continue to support the #TB community to increase access to life saving medicines. https://lnkd.in/gUnjkRmW #WorldTBDay #YesWeCan #endTB

🌟 Join Our Mission at Medicines for All (M4ALL) - We're Hiring a Head of R&D! 🔬 Are you passionate about making a global impact in access to medicines? Medicines for All (M4ALL), a dynamic part of Virginia Commonwealth University, is seeking a visionary Head of R&D to lead our efforts in improving access to affordable medications worldwide. 🌍 As the Head of R&D, you'll be at the forefront of developing innovative, cost-effective solutions for producing active pharmaceutical ingredients (APIs). This is more than a job – it's a chance to make a tangible difference in global health. 📧 Ready to make a difference? Apply now and join us in our journey to improve global health access!

As many in the TB community prepare to gather in Paris next week for the International Union Against Tuberculosis and Lung Disease (The Union) Conference, M4ALL is pleased to share our work on improving the manufacturing processes of active pharmaceutical ingredients (API) for priority TB drugs: bedaquiline, pretomanid, sutezolid and OPC-167832. These improved processes have the potential to lower raw material costs and improve manufacturability of these drugs. All of the processes are freely available and published open access on our website: https://lnkd.in/dsA6yFcs. If you are interested in partnering with us to use this work, please reach out to the team at m4all@vcu.edu. We will provide spotlights on each of these projects leading up to the conference next week: Bedaquiline: M4ALL developed two processes that demonstrate the potential to reduce the raw material cost for the active pharmaceutical ingredient (API) of bedaquiline fumarate ("bedaquiline"). Project Details: https://lnkd.in/dSb-5XHS Pretomanid: M4ALL worked with several collaborators whose collective improvements to the API synthetic process could provide a safer route to a key intermediate and allow for the use of commodity starting materials, thus providing the API at lower raw material cost. Project Details: https://lnkd.in/dQeRZX4S Sutezolid: M4ALL made improvements to the synthesis of a key intermediate of sutezolid which could lower raw material costs of the API. Project Details: https://lnkd.in/dzEPX3Q9 OPC-167832: M4ALL developed a concise process to prepare the key dihydroquinolone intermediate used to make the API by using commodity raw materials. Project Details: https://lnkd.in/d39vBQYG #tuberculosis #bedaquiline #pretomanid #sutezolid #AccesstoMedicine #GlobalHealth #UnionConf2023

Medicines for All is a proud member of the Alliance for Building Better Medicine and partner to so many innovative organizations in the Richmond-Petersburg area who are working to make advances in pharmaceutical manufacturing. We are grateful for the recognition of the region as a designated U.S. Economic Development Administration Tech Hub and are excited to continue to our collaborations to ensure that medicines are accessible to all who need them. From our founder and CEO, Frank Gupton: “The research at the Medicines for All Institute at Virginia Commonwealth University over the past decade was foundational to the building of an APM cluster in the Region, but without the strong partnerships we’ve developed through our work as an Alliance we would not have had the opportunity to change the landscape for medicine manufacturing for the nation and beyond. The shared successes over the past several years are extraordinary and we’re excited to see it grow and amplify through the investments of the EDA and this designation as an APM Tech Hub." #partnership #medicine #manufacturing #techhub #innovation